Nothing Special   »   [go: up one dir, main page]

SG11201909960UA - Methods for improving memory and cognition and for treating memory and cognitive disorders - Google Patents

Methods for improving memory and cognition and for treating memory and cognitive disorders

Info

Publication number
SG11201909960UA
SG11201909960UA SG11201909960UA SG11201909960UA SG 11201909960U A SG11201909960U A SG 11201909960UA SG 11201909960U A SG11201909960U A SG 11201909960UA SG 11201909960U A SG11201909960U A SG 11201909960UA
Authority
SG
Singapore
Prior art keywords
international
memory
cognition
pct
methods
Prior art date
Application number
Inventor
Yuri Maricich
Original Assignee
Cavion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion Inc filed Critical Cavion Inc
Publication of SG11201909960UA publication Critical patent/SG11201909960UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT Hu omit VIII °nolo loollowo oimIE (10) International Publication Number WO 2018/200850 Al (51) International Patent Classification: C07D 401/06 (2006.01) C07D 413/14 (2006.01) (21) International Application Number: PCT/US2018/029616 (22) International Filing Date: 26 April 2018 (26.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/490,377 26 April 2017 (26.04.2017) US (71) Applicant: CAVION, INC. [US/US]; 600 East Water Street, Suite E, Charlottesville, VA 22902 (US). (72) Inventor: MARICICH, Yuri; 977 Seminole Trail, #357, Charlottesville, VA 22901 (US). (74) Agent: WILLIS, Margaret, S., J.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) CZ 11 00 O O el (54) Title: METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS 1-1 O (57) : This disclosure provides methods for the treatment of disease by administering pharmaceutical compounds. In particular, \" the disclosure relates to the treatment to improve memory or cognition, or to treat a memory or cognitive disorder, or to treat cognitive 0 symptoms of a disease or condition by administering a T-type calcium channel antagonist.
SG11201909960U 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders SG11201909960UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490377P 2017-04-26 2017-04-26
PCT/US2018/029616 WO2018200850A1 (en) 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders

Publications (1)

Publication Number Publication Date
SG11201909960UA true SG11201909960UA (en) 2019-11-28

Family

ID=63920133

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909960U SG11201909960UA (en) 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders
SG10202111885PA SG10202111885PA (en) 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202111885PA SG10202111885PA (en) 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders

Country Status (11)

Country Link
US (1) US11324733B2 (en)
EP (1) EP3615521A4 (en)
JP (1) JP7321097B2 (en)
KR (1) KR102654466B1 (en)
CN (1) CN110770221B (en)
AU (1) AU2018260699B2 (en)
CA (1) CA3061720A1 (en)
IL (1) IL270180B (en)
MX (1) MX2019012818A (en)
SG (2) SG11201909960UA (en)
WO (1) WO2018200850A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102642063B1 (en) 2017-02-15 2024-03-04 카비온, 인코포레이티드 calcium channel inhibitor
SG11201909960UA (en) 2017-04-26 2019-11-28 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
IL300798A (en) 2018-10-03 2023-04-01 Cavion Inc Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
JP7553453B2 (en) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド Gamma-hydroxybutyrate compositions with improved pharmacokinetics under fed conditions - Patents.com
CA3221518A1 (en) * 2021-06-07 2022-12-15 Atsufumi Kawabata T-type calcium channel blocker
CN114129733A (en) * 2021-12-08 2022-03-04 中国科学院深圳先进技术研究院 Medicine for relieving anxiety and related energy metabolism disorder and application thereof
CN116392490A (en) * 2021-12-27 2023-07-07 中国科学院广州生物医药与健康研究院 Use of flunarizine and method for controlling intracellular mitochondrial number
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN114601928B (en) * 2022-04-02 2023-03-17 首都医科大学 Marker for calcium overload mediated neuronal death and application
WO2024152149A1 (en) * 2023-01-16 2024-07-25 南京纽邦生物科技有限公司 N-arachidonoyl ethanolamine composition and use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK171349B1 (en) 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalane derivatives, process for their preparation, medicaments containing the compounds and use of the compounds for the manufacture of medicaments
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
WO2002082970A2 (en) 2001-04-06 2002-10-24 The Research Foundation Of The City University Of New York Diagnosis and treatment of neural disease and injury using microvoltammetry
JP4491240B2 (en) 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5, and methods of use thereof
EP1553946A4 (en) * 2002-10-17 2008-07-16 Merck & Co Inc Enhancement of sleep with t-type calcium channel antagonists
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP2006520799A (en) 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド Methods for treating lower urinary tract disorders using smooth muscle regulators and α2δ subunit calcium channel regulators
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
KR100610731B1 (en) 2004-02-24 2006-08-09 한국과학기술연구원 3,4-Dihydroquinazoline Derivatives as T-Type Calcium Channel Blockers and Process for the Preparation Thereof
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
JP4927735B2 (en) 2004-08-20 2012-05-09 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン T-type calcium channel inhibitor
CA2576186A1 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
KR20070110081A (en) 2005-03-09 2007-11-15 머크 앤드 캄파니 인코포레이티드 Quinazolinone t-type calcium channel antagonists
AU2006262101A1 (en) 2005-06-23 2007-01-04 Merck & Co., Inc. 3-fluoro-piperidine T-type calcium channel antagonists
EP1901746B1 (en) * 2005-06-29 2013-02-20 Merck Sharp & Dohme Corp. 4-fluoro-piperidine t-type calcium channel antagonists
WO2007007852A1 (en) 2005-07-14 2007-01-18 Teijin Chemicals Ltd. Foamed resin sheet and liquid crystal display
KR100654328B1 (en) 2005-08-26 2006-12-08 한국과학기술연구원 Piperazynylalkylpyrazole devrivatives useful as selective t-type calcium channel blockers and preparation method thereof
EP1968956A2 (en) 2005-12-22 2008-09-17 Icagen, Inc. Calcium channel antagonists
WO2007120729A2 (en) 2006-04-12 2007-10-25 Merck & Co., Inc. Pyridyl amide t-type calcium channel antagonists
KR100743255B1 (en) 2006-05-04 2007-07-27 한국과학기술연구원 Novel 1,3-dioxoisoindole derivatives having selective antagonism of t-type calcium channel
KR100749843B1 (en) 2006-07-13 2007-08-21 한국과학기술연구원 2,4-quinazoline deivatives having activity to t-type calcium channel and preparation method thereof
KR100969686B1 (en) 2006-08-07 2010-07-14 한국과학기술연구원 Novel thiazole-based compound and inhibitor of t-type calcium channel
MX2009002921A (en) 2006-09-15 2009-04-01 Schering Corp Azetidinone derivatives for the treatment of disorders of the lipid metabolism.
US7638526B2 (en) 2006-09-15 2009-12-29 Schering Corporation Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2663947A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
US20080070892A1 (en) 2006-09-15 2008-03-20 Harris Joel M Treating pain, diabetes, and disorders of lipid metabolism
CN101528227A (en) 2006-09-15 2009-09-09 先灵公司 Azetidinone derivatives and methods of use thereof
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
EP2073799A4 (en) * 2007-03-12 2009-08-19 Vm Discovery Inc Novel agents of calcium ion channel modulators
WO2008117148A1 (en) 2007-03-23 2008-10-02 Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
KR100863239B1 (en) 2007-05-23 2008-10-15 한국과학기술연구원 Novel 2-imino-1,3-thiazoline-based compounds and t-type calcium channel inhibitors containing the same
EP2175725A1 (en) 2007-07-10 2010-04-21 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
KR101079459B1 (en) 2007-09-14 2011-11-03 이화여자대학교 산학협력단 Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain
AU2008317352A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
AU2008317351A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Pyrazinyl amide T-type calcium channel antagonists
BRPI0818244A2 (en) 2007-10-24 2015-06-16 Merck Sharp & Dohme Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease
WO2009056934A1 (en) 2007-10-31 2009-05-07 Pfizer Products Inc. 1,4-dihydronaphthyridine derivatives
KR100917037B1 (en) 2007-11-01 2009-09-10 한국과학기술연구원 Novel pyrazolcarboxamidoalkylpiperazine devrivatives and preparation method thereof
CA2722706A1 (en) 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
KR20110071050A (en) * 2008-04-29 2011-06-28 파넥스트 Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
KR101014887B1 (en) 2008-06-26 2011-02-15 한국과학기술연구원 Novel imidazoylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof
KR20100005476A (en) 2008-07-07 2010-01-15 한국과학기술연구원 Novel isoindolinone derivatives having activity for t-type calcium channel
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
KR101052620B1 (en) 2008-08-28 2011-07-29 한국과학기술연구원 Novel phenylacetate derivative or pharmaceutically acceptable salt thereof, preparation method thereof and composition for the prevention or treatment of diseases caused by the activity of T-type calcium ion channel containing the same as an active ingredient
KR101052065B1 (en) 2008-10-15 2011-07-27 한국과학기술연구원 Pyrazolylmethylamine-piperazine Derivatives Effective as Calcium Ion Channel Regulators and Methods for Preparing the Same
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
SG10201402863PA (en) 2009-06-05 2014-10-30 Tau Therapeutics Llc Interlaced method for treating cancer or a precancerous condition
BR112012003179A2 (en) 2009-08-12 2016-03-01 Carlos Alberto Barcelo Rojas bioelectronic system
US20130036482A1 (en) 2010-01-29 2013-02-07 National University Corporation Okayama University Method for assessment of potential for development of dravet syndrome and use thereof
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US20140004186A1 (en) 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2012094615A2 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Use of cav3.1 selective t-type calcium channel antagonists
BR112014028041A2 (en) 2012-05-08 2017-06-27 Zafgen Inc treatment of hypothalamic obesity with metap2 inhibitors
AU2014205255A1 (en) 2013-01-10 2015-07-23 Cavion, Inc. T-type calcium channel inhibitors for treatment of cancer
WO2015149066A1 (en) 2014-03-28 2015-10-01 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic
KR101679262B1 (en) 2015-06-08 2016-11-24 한국과학기술연구원 4-Isopropylchroman-3-ol derivatives
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3364993B1 (en) * 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
CN105534977A (en) * 2016-01-14 2016-05-04 山东大学 Application of T-type calcium ion channel inhibitor NNC55-0396 to preparation of drug resisting neurodegenerative disease
SG11201909960UA (en) 2017-04-26 2019-11-28 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
IL270137B2 (en) 2017-04-26 2024-04-01 Cavion Inc T-type calcium channel antagonist for use in treating dravet syndrome
GB2571978A (en) * 2018-03-15 2019-09-18 Andre Fisahn Uses, compositions and methods
IL300798A (en) 2018-10-03 2023-04-01 Cavion Inc Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
TW202122084A (en) 2019-10-02 2021-06-16 美商卡凡恩公司 Methods and materials for treating neurotoxicity

Also Published As

Publication number Publication date
CN110770221B (en) 2023-09-08
EP3615521A1 (en) 2020-03-04
SG10202111885PA (en) 2021-12-30
CN110770221A (en) 2020-02-07
AU2018260699B2 (en) 2022-04-28
MX2019012818A (en) 2020-07-14
RU2019137952A3 (en) 2021-05-31
EP3615521A4 (en) 2021-02-17
WO2018200850A1 (en) 2018-11-01
US11324733B2 (en) 2022-05-10
KR20200003394A (en) 2020-01-09
JP2020517701A (en) 2020-06-18
AU2018260699A1 (en) 2019-11-14
JP7321097B2 (en) 2023-08-04
RU2019137952A (en) 2021-05-26
CA3061720A1 (en) 2018-11-01
KR102654466B1 (en) 2024-04-08
US20200197377A1 (en) 2020-06-25
IL270180B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201907034PA (en) Methods of treating influenza
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201909224QA (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201809702SA (en) Benzenesulfonamide compounds and their use as therapeutic agents
SG11201811804QA (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201811311VA (en) Compounds for imaging tau protein aggregates
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201806157WA (en) Method and pharmaceutical composition for treatment of neurodegeneration
SG11201810358YA (en) Compositions and methods for treating negative symptoms in non-schizophrenic patients